ATE541584T1 - Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer - Google Patents

Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer

Info

Publication number
ATE541584T1
ATE541584T1 AT06850448T AT06850448T ATE541584T1 AT E541584 T1 ATE541584 T1 AT E541584T1 AT 06850448 T AT06850448 T AT 06850448T AT 06850448 T AT06850448 T AT 06850448T AT E541584 T1 ATE541584 T1 AT E541584T1
Authority
AT
Austria
Prior art keywords
metastasis
endogene
inhibitors
person
met
Prior art date
Application number
AT06850448T
Other languages
English (en)
Inventor
Fariba Nayeri
Tayeb Nayeri
Original Assignee
Fariba Nayeri
Tayeb Nayeri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fariba Nayeri, Tayeb Nayeri filed Critical Fariba Nayeri
Application granted granted Critical
Publication of ATE541584T1 publication Critical patent/ATE541584T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT06850448T 2005-11-16 2006-11-16 Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer ATE541584T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73733105P 2005-11-16 2005-11-16
PCT/IB2006/003944 WO2007110698A2 (en) 2005-11-16 2006-11-16 Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors

Publications (1)

Publication Number Publication Date
ATE541584T1 true ATE541584T1 (de) 2012-02-15

Family

ID=38541481

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850448T ATE541584T1 (de) 2005-11-16 2006-11-16 Verfahren zur hemmung von krebsbildung und/oder metastasen bei einer person durch endogene c-met- liganden und -hemmer

Country Status (5)

Country Link
US (1) US20090068179A1 (de)
EP (1) EP1957102B1 (de)
CN (1) CN101360511A (de)
AT (1) ATE541584T1 (de)
WO (1) WO2007110698A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3165538A1 (de) 2010-11-03 2017-05-10 Argen-X Nv Anti-c-met-antikörper
EP2773660A2 (de) 2011-11-03 2014-09-10 Argen-X B.V. Chimäre mensch-kamel-antigene und ihre verwendung
ES2927651T3 (es) * 2013-04-04 2022-11-10 Exelixis Inc Forma de dosificación de cabozantinib y uso en el tratamiento del cáncer
EP3042192A4 (de) * 2013-09-04 2017-04-26 Sten Ohlson Schwache affinitätschromatografie
MX378108B (es) 2014-09-16 2025-03-10 Servier Lab Anticuerpos anti-met y composiciones.
TWI782930B (zh) 2016-11-16 2022-11-11 美商再生元醫藥公司 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法
CN114340684B (zh) 2019-09-16 2025-09-12 瑞泽恩制药公司 用于免疫pet成像的放射性标记的met结合蛋白

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
JP3832674B2 (ja) * 1995-10-24 2006-10-11 敏一 中村 抗癌剤
EP1840575A1 (de) * 2000-08-28 2007-10-03 Damavand Wound AB Kit zur Bestimmung von HGF
MXPA05008521A (es) * 2003-02-13 2005-10-20 Pharmacia Corp Anticuerpos a c-met para el tratamiento de canceres.
HN2004000285A (es) * 2003-08-04 2006-04-27 Pfizer Prod Inc ANTICUERPOS DIRIGIDOS A c-MET
US20070224703A1 (en) * 2003-09-29 2007-09-27 Fariba Nayeri Rapid Determination of Hepatocyte Growth Factor (Hgf) in the Body Fluids
CN1922208A (zh) * 2003-12-11 2007-02-28 健泰科生物技术公司 用于抑制c－met二聚化及活化的方法和组合物
JP2008516629A (ja) * 2004-10-20 2008-05-22 ペアス インスティテュート アーベー 肝細胞増殖因子（ｈｇｆ）の生物活性に関する評価

Also Published As

Publication number Publication date
WO2007110698A3 (en) 2008-02-21
EP1957102A2 (de) 2008-08-20
CN101360511A (zh) 2009-02-04
EP1957102B1 (de) 2012-01-18
WO2007110698A2 (en) 2007-10-04
US20090068179A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
BRPI0611670A2 (pt) método para o tratamento ou prevenção de câncer em um indivíduo
ATE404574T1 (de) Verfahren zur inhibierung der proliferation von tumorzellen, bei dem platinkomplexe eingesetzt werden
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
DK1893196T3 (da) Diarylhydantoin-forbindelse
CY1111714T1 (el) Δεσμευτικες πρωτεϊνες αυξητικου παραγοντα ηπατοκυτταρων (hgf).
EA200600689A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов raf киназы
ATE294591T1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
DE602004022982D1 (de) Verwendung von treprostinil zur verbesserung der nierenfunktion
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
ATE471334T1 (de) Phosphoramidatderivate von nukleosidverbindungen zur verwendung bei der behandlung von krebs
ATE521357T1 (de) Verfahren zur behandlung von hepatitis
ATE548359T1 (de) Verbindungen und verfahren zur inhibierung der wechselwirkung von bcl-proteinen mit bindungspartnern
ATE485517T1 (de) Verfahren zur identifizierung von polypeptid- targets
TW200706682A (en) Unsymmetrical ligand sources, reduced symmetry metal-containing compounds, and systems and methods including same
BR0314369A (pt) Métodos para inibir o crescimento de uma célula, para induzir morte celular de uma célula de câncer, para tratar ou prevenir câncer em um indivìduo e para identificar um agente que inibe o crescimento canceroso de uma célula, agente, e, anticorpo ephb4 purificado
DE50207332D1 (de) Phosphonite, ihre verwendung als ligand in übergangsmetall komplexen und verfahren zur herstellung von nitrilen
MX2020013894A (es) Anticuerpos anti-factor xii/xiia y usos de los mismos.
ATE512146T1 (de) Phenylharnstoffderivate als hemmstoffe von tyrosinkinasen zur behandlung von tumorerkrankungen
WO2007110698A3 (en) Methods for inhibiting carcinogenesis and/or metastasis in an individual with endogenous c-met ligands and inhibitors
TW200716132A (en) Novel chemical compounds
EP1968981A4 (de) Verfahren zur behandlung von tumoren mit azaxanthonen
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005007220D1 (de) Tetrahydropyridothiophenen zur verwendung in der behandlung von krebs